TaiwanJ Pharmaceuticals Co., Ltd. (TPEX:6549)
Taiwan
· Delayed Price · Currency is TWD 7.68
-0.02 (-0.26%)
At close: Mar 10, 2026
TaiwanJ Pharmaceuticals Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Revenue | - | - | 22.74 | 15.36 | 22.06 | - | Upgrade
|
| Revenue Growth (YoY) | - | - | 48.11% | -30.38% | - | - | Upgrade
|
| Cost of Revenue | - | - | - | 75.28 | - | - | Upgrade
|
| Gross Profit | - | - | 22.74 | -59.92 | 22.06 | - | Upgrade
|
| Selling, General & Admin | 14.51 | 15.64 | 15.38 | 12.98 | 14.05 | 14.4 | Upgrade
|
| Research & Development | 10.61 | 11.31 | 13.97 | 12.74 | 17.73 | 25.98 | Upgrade
|
| Operating Expenses | 25.12 | 26.96 | 29.35 | 36.47 | 31.78 | 40.38 | Upgrade
|
| Operating Income | -25.12 | -26.96 | -6.61 | -96.39 | -9.73 | -40.38 | Upgrade
|
| Interest Expense | -0.03 | -0.01 | -0.02 | -0.01 | -0.01 | -0.03 | Upgrade
|
| Interest & Investment Income | 1.75 | 2.1 | 2.52 | 0.49 | 0.04 | 0.09 | Upgrade
|
| Currency Exchange Gain (Loss) | -1.97 | 2.53 | 0.33 | 3.29 | -0.62 | -0.51 | Upgrade
|
| Other Non Operating Income (Expenses) | 0.01 | - | 0.01 | 0.16 | - | -1.63 | Upgrade
|
| EBT Excluding Unusual Items | -25.36 | -22.34 | -3.77 | -92.47 | -10.32 | -42.46 | Upgrade
|
| Pretax Income | -25.36 | -22.34 | -3.77 | -92.47 | -10.32 | -42.46 | Upgrade
|
| Income Tax Expense | - | - | 2.27 | - | 2.11 | - | Upgrade
|
| Net Income | -25.36 | -22.34 | -6.05 | -92.47 | -12.42 | -42.46 | Upgrade
|
| Net Income to Common | -25.36 | -22.34 | -6.05 | -92.47 | -12.42 | -42.46 | Upgrade
|
| Shares Outstanding (Basic) | 79 | 77 | 75 | 75 | 75 | 71 | Upgrade
|
| Shares Outstanding (Diluted) | 79 | 77 | 75 | 75 | 75 | 71 | Upgrade
|
| Shares Change (YoY) | 5.22% | 1.89% | - | 0.03% | 6.07% | 2.98% | Upgrade
|
| EPS (Basic) | -0.32 | -0.29 | -0.08 | -1.23 | -0.17 | -0.60 | Upgrade
|
| EPS (Diluted) | -0.32 | -0.29 | -0.08 | -1.23 | -0.17 | -0.60 | Upgrade
|
| Free Cash Flow | -22.44 | -22.62 | -2.26 | -22.3 | -10.05 | -41.28 | Upgrade
|
| Free Cash Flow Per Share | -0.28 | -0.30 | -0.03 | -0.30 | -0.13 | -0.58 | Upgrade
|
| Gross Margin | - | - | 100.00% | - | 100.00% | - | Upgrade
|
| Operating Margin | - | - | -29.07% | -627.77% | -44.09% | - | Upgrade
|
| Profit Margin | - | - | -26.59% | -602.20% | -56.32% | - | Upgrade
|
| Free Cash Flow Margin | - | - | -9.95% | -145.22% | -45.56% | - | Upgrade
|
| EBITDA | -24.13 | -25.76 | -5.29 | -20.49 | -9.12 | -39.67 | Upgrade
|
| EBITDA Margin | - | - | -23.28% | -133.41% | -41.37% | - | Upgrade
|
| D&A For EBITDA | 0.99 | 1.19 | 1.32 | 75.91 | 0.6 | 0.7 | Upgrade
|
| EBIT | -25.12 | -26.96 | -6.61 | -96.39 | -9.73 | -40.38 | Upgrade
|
| EBIT Margin | - | - | -29.07% | - | -44.09% | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.